Ricevi le ultime notizie sulle azioni Cyclerion Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CYCN

Ultime notizie per

Cyclerion Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics Inc

AIM ImmunoTech

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

GRI Bio

HCW Biologics

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revolution Medicines

SILO Pharma

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

Cyclerion Therapeutics (CYCN) Previsione

Notizie

Utili

Insider trading

Vendite allo scoperto

Rapporto azionario

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Comments

Cyclerion Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO